[Form 4] CITIUS ONCOLOGY, INC. Insider Trading Activity
Rhea-AI Filing Summary
Reporting person: Dennis M. McGrath, Director of Citius Oncology, Inc. (CTOR). Transaction: On 09/19/2025 Mr. McGrath was granted 300,000 restricted common shares at $0, which vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to continued service. He also holds two previously reported option grants: a $1.07 exercise-price option for 125,000 shares (granted 12/12/2024; vests one-third each year over three years) and a $2.15 exercise-price option for 150,000 shares (100% vested). Following the 09/19/2025 award, Mr. McGrath beneficially owns 300,000 shares directly plus the options described above. The Form 4 was signed by power of attorney on 09/23/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR Director received equity compensation aligning interests with shareholders; vesting tied to continued service.
The grant of 300,000 restricted shares to a director is a material director-level equity award that drives long-term alignment through time-based vesting. The award vests in three substantially equal annual installments, which is standard for retention-focused compensation. Combined with outstanding options (125,000 at $1.07 and 150,000 at $2.15), the director has both immediate in-the-money/near-term economic interest and longer-term vested equity exposure. This structure signals typical governance practice to retain and incentivize key board-level contributors without immediate dilution from open-market issuance since the restricted shares are subject to forfeiture until vesting.
TL;DR Equity issuance increases potential share count; economics depend on vesting and option exercise behavior.
The Form 4 discloses a 09/19/2025 restricted stock award of 300,000 shares at $0 and two option grants totaling 275,000 underlying shares. One option series is exercisable at $1.07 for 125,000 shares (time-vesting from 12/12/2024) and the other at $2.15 for 150,000 shares (fully vested). For investors, the important metrics are the fixed share counts and exercise prices disclosed here; the immediate reported beneficial ownership post-transaction is 300,000 direct shares plus the documented options. The filing does not provide company-wide share count or percentage ownership, so precise dilution impact cannot be calculated from this Form 4 alone.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 300,000 | $0.00 | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date. These options are 100% vested.
